Results 31 to 40 of about 10,900 (261)

Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. [PDF]

, 2014
OBJECTIVE: To examine the timing and duration of RSV bronchiolitis hospital admission among term and preterm infants in England and to identify risk factors for bronchiolitis admission.
A Bottle, A Bush, Alex Bottle, Azeem Majeed, B Muller-Pebody, BJ Law, BN Manktelow, C Wren, CB Hall, CB Hall, CG Garcia, D Wang, DK Shay, GK Spurling, H Nair, H Patel, J Barben, J Murray, Joanna Murray, JS Tregoning, L Bont, LG Stensballe, M Koehoorn, Mike Sharland, ML Houben, Neena Modi, NG Papadopoulos, Oliver Schildgen, P Aylin, Paul Aylin, RL Smyth, S Beck, S Ladhani, S Saxena, SA Deshpande, Sonia Saxena   +35 more
core   +3 more sources

Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands

Vaccines, 2023
Respiratory Syncytial Virus (RSV) poses a severe threat to infants, particularly preterm infants. Palivizumab, the standard preventive prophylaxis, is primarily utilized in high-risk newborns due to its cost.
R. Schepp, Joanna Kaczorowska, P. V. van Gageldonk, Elsbeth D. M. Rouers, Elisabeth A M Sanders, P. Bruijning-Verhagen, G. Berbers   +6 more
semanticscholar   +1 more source

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children

Drugs in Context, 2015
Background: The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. Additional monthly doses of palivizumab may be necessary in warmer regions to protect
Saleh al-Alaiyan, Paul Pollack, Gerard F Notario   +2 more
doaj   +1 more source

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state [PDF]

, 2017
Human respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children. The RSV fusion protein (F) is highly conserved and is the only viral membrane protein that is essential for infection.
Chen, Man, Gilman, Morgan SA, Graham, Barney S, Kabeche, Stephanie C, Kanekiyo, Masaru, Mas, Vicente, McLellan, Jason S, Melero, José A, Rossey, Iebe, Saelens, Xavier, Schepens, Bert, Sedeyn, Koen, Spitaels, Jan, Wrapp, Daniel   +13 more
core   +2 more sources

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age

PLoS ONE, 2023
Since the last Italian cost-utility assessment of palivizumab in 2009, new data on the burden of respiratory syncytial virus (RSV) and an International Risk Scoring Tool (IRST) have become available.
I. Keary, R. Ravasio, J. Fullarton, P. Manzoni, M. Lanari, B. Paes, X. Carbonell-Estrany, Eugenio Baraldi, J. Tarride, B. Rodgers-Gray   +9 more
semanticscholar   +1 more source

The Use of Aerosolized Ribavirin in Respiratory Syncytial Virus Lower Respiratory Tract Infections in Adult Immunocompromised Patients: A Systematic Review [PDF]

, 2019
Introduction: Respiratory syncytial virus (RSV)–associated lower respiratory tract infection (LRTI) is a concern in immunocompromised patients. Aerosolized ribavirin (RBV AER) is used for treatment of RSV LRTI; however, adverse events and rising drug ...
Avery, Lisa M., Hoffmann, Charles, Whalen, Karen M.   +2 more
core   +2 more sources

Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high‐risk infants

Pediatric Pulmonology, 2023
Uniformity and compliance with clinical practice guidelines (CPGs) for use of palivizumab in preventing severe respiratory syncytial viral infection in Australian high‐risk infants remain unclear.
Eunice Stiboy, M. Chan, M. Islam, G. Saravanos, K. Lui, A. Jaffe, N. Homaira   +6 more
semanticscholar   +1 more source

Initial Palivizumab Dose Administration in Outpatient Clinic After Hospital Discharge [PDF]

, 2018
BACKGROUND:Palivizumab provides passive immunity for respiratory syncytial virus (RSV), but poor adherence compromises protection. A hospital initiative promoted administration of first palivizumab doses at an outpatient clinic immediately after ...
Chen, Yanjun, Chilvers Murphy, Michelle, Jun, Allison, Lee, Tina, Magedman, Grace, Stockton, Winifred   +5 more
core   +1 more source

Respiratory syncytial virus–approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors

Journal of Biological Chemistry, 2023
Synthetic cytokine receptors can modulate cellular functions based on an artificial ligand to avoid off-target and/or unspecific effects. However, ligands that can modulate receptor activity so far have not been used clinically because of unknown ...
Julia Ettich, Christoph Wittich, Jens M. Moll, K. Behnke, D. Floss, Jens Reiners, Andreas Christmann, Philipp A. Lang, S. Smits, H. Kolmar, Jürgen Scheller   +10 more
semanticscholar   +1 more source

Infecções respiratórias em crianças menores de dois anos de idade submetidas a profilaxia com palivizumabe [PDF]

, 2014
OBJECTIVE: To identify the viruses involved in acute respiratory tract infections and to analyze the rates of hospitalization and death in children on palivizumab prophylaxis.METHODS:Prospective cohort of 198 infants up to one year old who were born ...
Bellei, Nancy Cristina Junqueira, Dos Santos, Amelia Miyashiro, Monteiro, Ana Isabel Melo Pereira, Sousa, Alessandra Ramos, Weckx, Lily Yin   +4 more
core   +3 more sources